InvestorsHub Logo
Followers 528
Posts 52930
Boards Moderated 0
Alias Born 05/14/2010

Re: None

Monday, 07/25/2016 11:28:57 AM

Monday, July 25, 2016 11:28:57 AM

Post# of 162
$40M cash in the bank to advance its R&D and clinical development of MGL-3196!


The combined company has more than $40 million in cash to advance its research and development efforts, including the clinical development of MGL-3196, Madrigal’s lead product candidate. MGL-3196 is a Phase 2-ready once-daily, oral, liver-directed selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of NASH and heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH).



http://ih.advfn.com/p.php?pid=nmona&article=72032827

Use your nose to sniff the winners out!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MDGL News